MedTrace Logo

Aspirin Resistance and Percutaneous Coronary Intervention (PCI)

NCT01103440 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2018-02-14

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate if aggressive antiplatelet therapy would reduce ischemic events in aspirin (ASA) resistant patients after percutaneous coronary intervention (PCI).

Conditions

  • Stable Angina

Interventions

DRUG

Intravenous Glycoprotein inhibitor + ASA, Clopidogrel

IV Glycoprotein IIb/IIIa inhibitor bolus intra procedurally

DRUG

Antiplatelet Therapy (ASA, Clopidogrel)

Standard antiplatelet PCI treatment

Sponsors & Collaborators

Principal Investigators

  • Annapoorna S Kini, MD MRCP · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2009-06-30
Completion
2009-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01103440 on ClinicalTrials.gov